EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models

Daniela D De Nobrega, Logan C Eiler, Parmanand Ahirwar iD, Sonika Nallapu, Urvi P Rawal, Chelsea L Crawford, Donald J Buchsbaum, Adam B Keeton, Yulia Y Maxuitenko iD, Xi Chen, Gary A Piazza iD, Allan Tsung und 1 weitere

Cancers · 10.09.2025 · 17 (18) · 2958

DOI: 10.3390/cancers17182958 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 10.09.2025. Verfasst von Daniela D De Nobrega und 12 weiteren Autor:innen. Beteiligte Einrichtung: CerFlux, Birmingham, AL 35203, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. National Science Foundation, NCI NIH HHS, Innovate Alabama.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) remains a significant global health burden, with KRAS mutations driving ~40% of cases. The efficacy of recently approved, mutant-specific KRAS inhibitors is limited by mutational status as well as intrinsic and adaptive resistance mechanisms. Pan-RAS inhibitors, such as ADT-007, offer broader therapeutic potential by targeting multiple RAS isoforms. Here, we evaluate ADT-007 in 3D bioprinted ex vivo slice tissue (BEST) generated from KRAS-mutant and RAS wild-type (WT) CRC cell lines.

Methods

Potency and selectivity of ADT-007 were benchmarked against bortezomib (proteasome inhibitor) and YM155 (survivin inhibitor) using high-content imaging and ATP-based luminescence assays. Apoptosis induction was assessed with Annexin V/propidium iodide and flow cytometry.

Results

ADT-007 exhibited high potency and selectivity in KRAS-mutant BEST, reducing tumor burdens >30% at nanomolar concentrations, and demonstrated superior selectivity with minimal cytotoxicity in WT RAS BEST. Annexin V staining confirmed selective induction of apoptosis in KRAS-mutant cells.

Conclusions

The selective potency and specificity of ADT-007 warrant further investigation of pan-RAS inhibitors for treating RAS-driven cancers. This study also underscores the translational utility of 3D BEST models for preclinical drug response assessment. Further validation in patient-derived BEST is necessary to evaluate the potential of ADT-007 in clinical settings.

Schlagwörter

Stichwörter der Autor:innen

3D bioprintingRAS mutationscolorectal cancerdrug discoveryex vivo tumor modelsnew approach methodspan-RAS inhibitors

Autor:innen und Institutionen

  • CerFlux, Birmingham, AL 35203, USA.
  • Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
  • Department of Surgery, School of Medicine, University of Virginia, Charlottesville, VA 22901, USA.

ORCID-Profile: Parmanand Ahirwar, Yulia Y Maxuitenko, Gary A Piazza, Karim I Budhwani

Förderung

  • U.S. National Science Foundation
  • NCI NIH HHS
  • Innovate Alabama
  • CerFlux, Innovate Alabama, the National Science Foundation
  • National Cancer Institute at the National Institutes of Health

Zitieren

APA

De Nobrega, D. D., Eiler, L. C., Ahirwar, P., Nallapu, S., Rawal, U. P., Crawford, C. L., Buchsbaum, D. J., Keeton, A. B., Maxuitenko, Y. Y., Chen, X., Piazza, G. A., Tsung, A., & Budhwani, K. I. (2025). Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models. Cancers, 17(18), 2958. https://doi.org/10.3390/cancers17182958

Vancouver

De Nobrega DD, Eiler LC, Ahirwar P, Nallapu S, Rawal UP, Crawford CL, et al. Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models. Cancers. 2025;17(18):2958. doi:10.3390/cancers17182958

BibTeX
@article{DeNobrega2025,
  author = {De Nobrega, Daniela D and Eiler, Logan C and Ahirwar, Parmanand and Nallapu, Sonika and Rawal, Urvi P and Crawford, Chelsea L and Buchsbaum, Donald J and Keeton, Adam B and Maxuitenko, Yulia Y and Chen, Xi and Piazza, Gary A and Tsung, Allan and Budhwani, Karim I},
  title = {Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {18},
  pages = {2958},
  doi = {10.3390/cancers17182958}
}
Kostenlos starten →